Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

View Press Release View All

May 3, 2022 • 4:01pm EDT

Rigel Reports First Quarter 2022 Financial Results and Provides Business Update

Apr 26, 2022 • 8:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update

Mar 8, 2022 • 8:05am EST

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology

May 2022

View Presentation

Rigel Conference Call to Discuss FORWARD Study Results

View Event View All

Q1 2022

Quarter Ended Mar 31, 2022

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080